NCT05961332Completed
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy (COCO-GA) Protocol
Source: ClinicalTrials.gov · Last updated 10 Jul 2026
Brief summary (registry, in English)
The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy. The main question to answer is which imaging device provides measurements that are most similar to the standard of care device. Participants will be patients of a retina doctor at University Station Eye Clinic with geographic atrophy, and can expect to be in the study for 60-75 minutes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 62 (actual)
- First submitted
- 18 Jul 2023
- Start date
- 6 Oct 2023
- Primary completion date
- 27 May 2025
- Lead sponsor
- University of Wisconsin, Madison
- Diseases
- Macular degeneration
- NCT number
- NCT05961332
What you commit to
- Study type: Interventional
- Participants enrolled: 62
- From 6 Oct 2023 to the primary completion date, 27 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of concurrent retinal disease which may confound assessment
Other
- Unable to tolerate opthalmic imaging
- Presence of neovascular AMD on OCT as confirmed by an ophthalmologist
- Presence of significant media opacity preventing adequate retinal imaging
Who the study is looking for
- 50 years or older and may be either male or female and may be of any race
- Established diagnosis of GA due to AMD
- GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude subjects from participation
- Willing to participate as evidenced by signing the written informed consent
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Wisconsin Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.